Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2018

08.11.2018 | short review

The impact of surgery in oligometastatic prostate cancer

verfasst von: Associate Professor Jasmin Bektic, MD, Professor Wolfgang Horninger, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Summary

Oligometastatic prostate cancer has been considered an intermediate state between localized disease and widespread metastases, but there is no consensus on the definition of oligometastasis in prostate cancer. At present, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies and post hoc analyses suggest that local or metastasis-directed interventions could have benefits in the oligometastatic state including a better response to systematic therapy, lower risk of local complications, and possible positive impact on cancer-specific survival and overall survival; however, insufficient data are available to draw reliable conclusions. In this short review, we summarize the current available data on the role of surgery in oligometastatic prostate cancer.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.CrossRefPubMed
2.
Zurück zum Zitat James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel era”: data from 917 patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.CrossRefPubMed James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel era”: data from 917 patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.CrossRefPubMed
4.
Zurück zum Zitat Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15–25.CrossRefPubMed Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15–25.CrossRefPubMed
5.
Zurück zum Zitat Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12.CrossRefPubMed Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12.CrossRefPubMed
6.
Zurück zum Zitat Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–8.CrossRefPubMed Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–8.CrossRefPubMed
7.
Zurück zum Zitat Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012;2:215.CrossRefPubMed Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012;2:215.CrossRefPubMed
8.
Zurück zum Zitat Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.CrossRefPubMed Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.CrossRefPubMed
9.
Zurück zum Zitat Sridharan S, Steigler A, Spry NA, et al. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol. 2016;121(1):98–102.CrossRefPubMed Sridharan S, Steigler A, Spry NA, et al. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol. 2016;121(1):98–102.CrossRefPubMed
10.
Zurück zum Zitat Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58(1):3–10.CrossRefPubMed Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58(1):3–10.CrossRefPubMed
11.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.CrossRefPubMed Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.CrossRefPubMed
12.
Zurück zum Zitat Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226–35.CrossRefPubMed Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226–35.CrossRefPubMed
13.
Zurück zum Zitat Aus G, Hugosson J, Norlen L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol. 1995;154(2 Pt 1):466–9.CrossRefPubMed Aus G, Hugosson J, Norlen L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol. 1995;154(2 Pt 1):466–9.CrossRefPubMed
14.
Zurück zum Zitat Patrikidou A, Brureau L, Casenave J, et al. Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome. Urol Oncol. 2015;33(5):202 e9–202 e17.CrossRef Patrikidou A, Brureau L, Casenave J, et al. Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome. Urol Oncol. 2015;33(5):202 e9–202 e17.CrossRef
16.
Zurück zum Zitat Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–11.CrossRefPubMed Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–11.CrossRefPubMed
17.
Zurück zum Zitat Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29(18):2574–81.CrossRefPubMedPubMedCentral Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29(18):2574–81.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22(17):3475–84.CrossRefPubMed Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22(17):3475–84.CrossRefPubMed
19.
Zurück zum Zitat Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.CrossRefPubMed Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.CrossRefPubMed
20.
Zurück zum Zitat Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.CrossRefPubMed Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.CrossRefPubMed
21.
Zurück zum Zitat Ghavamian R, Bergstralh EJ, Blute ML, et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999;161(4):1223–7. discussion 7–8.CrossRefPubMed Ghavamian R, Bergstralh EJ, Blute ML, et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999;161(4):1223–7. discussion 7–8.CrossRefPubMed
22.
Zurück zum Zitat Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002;168(3):1008–12.CrossRefPubMed Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002;168(3):1008–12.CrossRefPubMed
23.
Zurück zum Zitat Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.CrossRefPubMed Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.CrossRefPubMed
24.
Zurück zum Zitat Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602–3.CrossRefPubMed Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602–3.CrossRefPubMed
25.
Zurück zum Zitat Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010;57(5):754–61.CrossRefPubMed Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010;57(5):754–61.CrossRefPubMed
26.
Zurück zum Zitat Moschini M, Briganti A, Murphy CR, et al. Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy. Eur Urol. 2016;69(2):193–6.CrossRefPubMed Moschini M, Briganti A, Murphy CR, et al. Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy. Eur Urol. 2016;69(2):193–6.CrossRefPubMed
27.
Zurück zum Zitat Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013;112(4):E250–E5.CrossRefPubMed Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013;112(4):E250–E5.CrossRefPubMed
28.
Zurück zum Zitat Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832–8.CrossRefPubMed Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832–8.CrossRefPubMed
29.
Zurück zum Zitat Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int. 2018;121(2):225–31.CrossRefPubMed Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int. 2018;121(2):225–31.CrossRefPubMed
30.
Zurück zum Zitat Yao HH, Hong M, Corcoran NM, et al. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol. 2014;10(4):308–21.CrossRefPubMed Yao HH, Hong M, Corcoran NM, et al. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol. 2014;10(4):308–21.CrossRefPubMed
31.
Zurück zum Zitat Chao DH, Higgins JP, Brooks JD. Biochemical remission after resection of prostate cancer lung metastasis. Urology. 2004;63(3):584–5.CrossRefPubMed Chao DH, Higgins JP, Brooks JD. Biochemical remission after resection of prostate cancer lung metastasis. Urology. 2004;63(3):584–5.CrossRefPubMed
Metadaten
Titel
The impact of surgery in oligometastatic prostate cancer
verfasst von
Associate Professor Jasmin Bektic, MD
Professor Wolfgang Horninger, MD
Publikationsdatum
08.11.2018
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0456-3

Weitere Artikel der Ausgabe 4/2018

memo - Magazine of European Medical Oncology 4/2018 Zur Ausgabe